title: Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
abstract: OBJECTIVE
  Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with poor prognosis. The aim of this prospective study was to evaluate the efficacy of hepatic arterial infusion chemotherapy (HAIC) for patients with this disease.
  
  
  METHODS
  Eighteen HCC patients with PVTT were treated with HAIC via a subcutaneously implanted injection port. A course of chemotherapy consisted of daily cisplatin (10 mg for one hour) followed by 5-fluorouracil (250 mg for five hours) for five continuous days within a given week. The patients were scheduled to receive four consecutive courses of HAIC. Responders were defined in whom either a complete or partial response was achieved, while non-responders were defined based on stable or progressive disease status. The prognostic factors associated with survival after treatment were analyzed.
  
  
  RESULTS
  Six patients exhibited partial response to this form of HAIC (response rate=33%). The 3, 6, 9, 12 and 18-month cumulative survival rates for the 18 patients were 83%, 72%, 50%, 28%, and 7%, respectively. Median survival times for the six responders and 12 non-responders were 15.0 (range, 11-18) and 7.5 (range, 1-13) months, respectively. It was demonstrated by both univariate and multivariate analyses that the therapeutic response and hepatic reserve function were significant prognostic factors.
  
  
  CONCLUSIONS
  HAIC using low-dose cisplatin and 5-fluorouracil may be a useful alternative for the treatment of patients with advanced HCC complicated with PVTT. There may also be survival-related benefits associated with HAIC.
authors.affiliation: Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan, China. yungchihlai@hotmail.com
authors.forename: Yung-Chih
authors.initials: YC
authors.lastname: Lai
authors.forename: Cheng-Yen
authors.initials: CY
authors.lastname: Shih
authors.forename: Chin-Ming
authors.initials: CM
authors.lastname: Jeng
authors.forename: Sien-Sing
authors.initials: SS
authors.lastname: Yang
authors.forename: Jui-Ting
authors.initials: JT
authors.lastname: Hu
authors.forename: Yung-Chuan
authors.initials: YC
authors.lastname: Sung
authors.forename: Han-Ting
authors.initials: HT
authors.lastname: Liu
authors.forename: Shaw-Min
authors.initials: SM
authors.lastname: Hou
authors.forename: Chi-Hwa
authors.initials: CH
authors.lastname: Wu
authors.forename: Tzen-Kwan
authors.initials: TK
authors.lastname: Chen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D020246:Venous Thrombosis / Q000209:etiology*
chemical_list: D002945:Cisplatin; D005472:Fluorouracil